Crossmark

A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97

Crossref DOI link: https://doi.org/10.1186/s13148-018-0475-2

Published Online: 2018-03-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramalho-Carvalho, João

Gonçalves, Céline S.

Graça, Inês

Bidarra, David

Pereira-Silva, Eva

Salta, Sofia

Godinho, Maria Inês

Gomez, Antonio

Esteller, Manel

Costa, Bruno M.

Henrique, Rui

Jerónimo, Carmen http://orcid.org/0000-0003-4186-5345
Funding

Funding for this research was provided by:

Research Center of Portuguese Oncology Institute of Porto (FB-GEBC-27 and 19-CI-IPOP-2016)

FCT- Fundação para a Ciência e Tecnologia PhD fellowship (SFRH/BD/92786/2013)

IPO Porto (IPO/ESTIMA-1 NORTE-01-0145-FEDER-000027)

FCT (PCT: PEst- UID/DTP/00776/2013 and COMPETE: POCI-01-0145-FEDER-006868)

FCT-Fundação para a Ciência e a Tecnologia (IF/00601/2012)
License Information

Text and Data Mining valid from 2018-03-27
More Information

Article History

Received: 1 February 2018

Accepted: 19 March 2018

First Online: 27 March 2018

Ethics approval and consent to participate

: This study was approved by the institutional ethics committee [Comissão de Ética para a Saúde- Instituto Português de Oncologia do Porto Francisco Gentil, EPE (CES-IPOPFG-EPE 215/013)]. Moreover, in compliance with the Helsinki Declaration and after CES approval, informed consent was obtained for all patients.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.